U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07109518) titled 'uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies' on July 31.
Brief Summary: The aim of this study was to evaluate the safety and efficacy of uCD7 CART cells in the treatment of patients with relapsed/refractory CD7-positive hematologic malignancies. In this single-arm, open-label, single-center, Phase 1 clinical trial, two cohorts were set up: (1) relapsed and refractory AML cohort; and (2) relapsed and refractory T-ALL/LBL cohort. Each cohort was planned to enroll 4-12 patients. uCD7 CART cells will be administered intravenously to explore the MTD of each cohort using a 3+3 dose escalation and rapid titrat...